AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01874028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trientine dihydrochloride
Description: Patients will take their normal prescribed dose (x1) of trientine dihydrochloride 300mg
Study NCT01953302 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified open mesh technique
Description: We positioned mesh intraperitoneally so it can provide adequate mechanical support to the weakened abdominal wall. We also preserved hernia sack to conceal the mesh.
Study NCT02569697 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Intravaginal Ring
Study NCT02569697 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Vaginal Film
Study NCT00323375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQ-13
Description: A treatment dose of AQ-13 (1750 mg base) was administered orally to subjects randomized to AQ-13 over 3 days (as two capsules on days 1 and 2, plus one capsule on day 3).
Study NCT00323375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine (CQ) Treatment
Description: A treatment dose of CQ (1500 mg CQ base) was administered orally to subjects randomized to CQ over 3 days (as two capsules on days 1 and 2, and one capsule on day 3).
Study NCT02569697 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Vaginal Insert
Study NCT01353339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: 500mg, PO, once daily for 3 months
Study NCT01353339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levofloxacin
Description: 500mg, PO, once daily for 3 months
Study NCT01031329 — intervention group
Intervention type: PROCEDURE
Intervention: Tympanocenthesis and urine collection
Description: Fluid using needle aspiration is obtained from middle ear fluid. Urine is collected using a urine bag.
Study NCT04283240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 50 mg sildenafil, one dose
Study NCT04283240 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02824055 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to RO5545965 capsules orally daily in any of the three intervention period.
Study NCT02824055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matched to RO5545965 capsules orally daily in any of the three intervention period.
Study NCT04286035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Injection
Description: Femoral nerve block with 20 ml %0.375 bupivacaine
Study NCT04286035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Injection
Description: Adductor canal block with 20 ml %0.375 bupivacaine
Study NCT01471535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a
Description: patients were given peginterferon alfa-2a (40KD) (Pegasys®; Roche, Basel, Switzerland)180 µg by subcutaneous injection once weekly for 120 weeks
Study NCT00703365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib and Gemcitabine
Description: Sorafenib 400 mg po bid daily and Gemcitabine IV 1,000 mg/m2 on day 1,8, 15 of a 28-day cycle (up to 6 cycles), then followed by Sorafenib 400 mg po bid daily maintenance until disease progression.
Study NCT01469884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: The conversion will be performed abruptly for all patients. Calcineurin inhibitor will be discontinued one day before the day of conversion (Day 1). Everolimus will be introduced on day 1 at dose of 3 mg/d (1,5mg bid), and then everolimus trough levels will be adjusted to achieve 6-10 ng/ml.
Study NCT01469884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Trough level should be between 100 and 200ng/ml.
Study NCT01469884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Trough level should be between 5 and 10ng/ml.
Study NCT03074968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzydamine Hydrochloride
Description: Benzydamine Hydrochloride application
Study NCT03074968 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: normal saline application
Study NCT01823458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lottery Insurance
Study NCT01823458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Lottery
Study NCT01895868 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simulation-based ultrasound training
Study NCT03540901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACETAZOLAMIDE oral capsule
Description: Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3100m
Study NCT03540901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3100m
Study NCT03103529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Rehabilitation
Study NCT03103529 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Rehabilitation
Study NCT02791139 — intervention group
Intervention type: OTHER
Intervention: Cardiovascular Magnetic Resonance Imaging (MRI)
Description: Cardiovascular MRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create heart images.
Study NCT02791139 — intervention group
Intervention type: OTHER
Intervention: Echocardiography
Description: To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help us understand the type and severity of heart failure.
Study NCT02791139 — intervention group
Intervention type: OTHER
Intervention: Tonometry
Description: Tonometry is a noninvasive method to obtain arterial pressure waveform
Study NCT02791139 — intervention group
Intervention type: OTHER
Intervention: Genetic Testing (Blood)
Description: The blood will be stored for genetic tests and development of cell lines to study genetic risks for aging related diseases and cardiovascular disease.
Study NCT02791139 — intervention group
Intervention type: OTHER
Intervention: Hand-Grip Strength Measurement
Description: We will measure your hand grip strength using a standard hand dynamometer which is a portable meter that you will use your hands to press on.
Study NCT02791139 — intervention group
Intervention type: OTHER
Intervention: Body Fat Mass Analysis
Description: Body composition will be analysed by a body composition analyser machine onto which you will have to stand on.
Study NCT05939050 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Powered toothbrush
Description: Oral-B Powered toothbrush
Study NCT04288440 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Removal of epiretinal membrane and ILM
Study NCT04288440 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vitrectomy machine
Description: Pars plana vitrectomy
Study NCT02008539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC_apceth_101
Study NCT01154699 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilevel PAP (4 weeks)
Description: Subjects will use bilevel PAP each night for 4 weeks. The pressure levels will be adjusted by the investigators to increase lung volumes during the night.
Study NCT01154699 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care (4 weeks)
Description: Subjects will continue with their usual asthma care. Investigators will make no changes to their medications or other habits.
Study NCT01154699 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Washout Period (4 weeks)
Description: Subjects will continue with their usual asthma care in between the Usual Care and Bilevel PAP periods. Investigators will make no changes to their medications or other habits.
Study NCT02951416 — intervention group
Intervention type: OTHER
Intervention: patient registry (observation and biomaterial sampling)
Description: data are collected with patient questionnaires, additionally clinical data are collected at every routine visit and biomaterial is collected
Study NCT01774903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTS-fentanyl
Description: TTS-fentanyl patches releasing drug at the rate of 12.5 microgram (µg) per hour for 3 days. The patches will be replaced every 3 days until 30 days.
Study NCT03286959 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCR with calcium hydroxide
Study NCT03286959 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCR with RMGIC
Study NCT03286959 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCR with direct composite
Study NCT04946240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised (BRACE) Group
Description: Supervised (BRACE) protocol include static, dynamic and anticipatory balance exercises, chair rise, stair climbing and floor transfer comes under the category of resistance exercises. 6 minutes walk test, marching in space and cycling comes in aerobic. count reverse for 50 remember 5 words, 5 animals, repeat 5 words, spell forward and backwards and cont even numbers comes in cognitive exercises.
Study NCT04946240 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Balance Exercises Group
Description: The home plan included Balance and Resistance exercises of BRACE protocol were provided to the control group but that was not supervised. Control group participants were also same assessed as the S-BRACE group. Before giving the training plan for home, it was elaborated in detail. For the convenience of participants, the BRACE protocol was also translated into Urdu and was given in the printed form. The data were collected at baseline, after 3 weeks, 6, 9 and then after 12 weeks of training
Study NCT03230279 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sacroiliac joint fusion
Description: Minimally invasive SIJ fusion will be performed under general anesthesia with fluoroscopy. Using SI-LOK®, Sacroiliac Joint Fixation System, Globus Medical Inc. (Audubon, PA), this procedure involve placement of 2 to 3 implants across the SIJ to achieve stabilization and arthrodesis.
Study NCT03230279 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sacroiliac joint radiofrequency ablation
Description: Sacroiliac joint radio frequency ablation will be performed using either conventional or cooled radiofrequency ablation techniques aimed at the S1-S3 lateral branches and the L5 dorsal ramus. The choice between conventional or cooled RFN will be determined by the provider expertise.
Study NCT00000254 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 40% Nitrous oxide
Description: Used as pain assay positive control
Study NCT00000254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40% Nitrous oxide
Description: Used as pain assay positive control
Study NCT00000254 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: 0% isoflurane in oxygen
Study NCT00000254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2% isoflurane
Study NCT00000254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.4% isoflurane
Study NCT00000254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.6% isoflurane
Study NCT03466060 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Opti-Free : RevitaLens / Clear Care : RevitaLens
Description: Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
Study NCT03466060 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Opti-Free : RevitaLens / RevitaLens : Clear Care
Description: Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
Study NCT03466060 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear Care : RevitaLens/ Opti-Free : RevitaLens
Description: Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
Study NCT04892004 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom recognition
Description: The patient receives a leaflet, which includes information about HF, primary symptoms, awareness of its detection and the fluid management plan. It also receives a weight diary, which helps him/her recall weight fluctuation and contact the nurse or doctor to call for help in a previous stage and avoid hospitalisation. Patients have to explain what they understand by HF, on follow-ups contacts, which are the main symptoms, if they are experiencing any of them and which difficulties managing fluid restriction and weight control. The leading investigator validates the information and teaches back contents if required.
Study NCT01690286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38518168 3 mg
Description: One oral daily dose of JNJ-38518168 3 mg for 25 days.
Study NCT01690286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38518168 30 mg
Description: One oral daily dose of JNJ-38518168 30 mg for 25 days.
Study NCT01690286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38518168 10 mg
Description: One oral daily dose of JNJ-38518168 10 mg for 25 days.
Study NCT01690286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg
Description: Oral doses of ketoconazole 200 mg every 12 hours, from Day 22 through Day 25.
Study NCT03188549 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AniosGel 85 NPC
Description: Hand hygiene formula
Study NCT03466060 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear Care : RevitaLens / RevitaLens : Opti-Free
Description: Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
Study NCT02824055 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RO5545965
Description: Participants will receive RO5545965 5 mg capsules or RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily in any of the three intervention period.
Study NCT02824055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5545965
Description: Participants will receive RO5545965 5 mg capsules or RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily in any of the three intervention period.
Study NCT02783495 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Device: iPad
Description: All patients will receive baseline neurocognitive and quality of life testing, followed by 3 months of the iPad-based intervention. At the end of the baseline visit, subjects will be lent an iPad to take home (or will be assisted in the installation of the ReMind app on their personal iPad) and instructed in the use of the ReMind app (and more basic iPad skills, if necessary). Subjects will review the intervention schedule (approximately 3 hours per week). Testing will be repeated 3 months after the baseline visit (i.e., immediately after the intervention) and 9 months after the baseline visit (i.e., 6 months after completion of the intervention), both time-points including a new MRI.
Study NCT03466060 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RevitaLens : Clear Care/ Opti-Free : RevitaLens
Description: Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
Study NCT03466060 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RevitaLens : Clear Care / RevitaLens : Opti-Free
Description: Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
Study NCT01918345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Physical Activity Program with Health Coach
Description: This arm will receive either a trained CDE or R. Kin as a health coach and a home-based physical activity program for 6 months. Health coaches will provide one-on-one motivational interviewing (MI) and goal-setting, and will account for baseline fitness, resources, childcare, and breastfeeding, to be undertaken at participants' homes or in their communities. Prescriptions will be based on minimum recommendations for moderate-intensity exercise for postpartum women. Participants will maintain at least 150 min/week of moderate activity at a target heart rate of 30-80% with a perceived exertion of 12-15 on the Borg Scale. They will also be counseled on resistance training and pelvic floor exercises. They will receive regular telephone-based coaching to advance goals. Phone-calls will be administered on a weekly basis during weeks 2-8 of the intervention, biweekly basis on weeks 10-12, and monthly basis on weeks 16-24.
Study NCT03466060 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RevitaLens : Opti-Free / Clear Care : RevitaLens
Description: Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
Study NCT01918345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Low-GI Diet Program with Health Coach
Description: This arm will receive a trained CDE health coach and a home-based low-GI diet program for 6 months. Health coaches will provide baseline education during a one-on-one visit and use MI to introduce the dietary intervention. Low GI education will be layered on top of current standard care, which asks women to consume a diet comprised of 45-65% carbohydrates (25 g of dietary fibre), 10-30% protein, and 25-35% fat. As per standard care at the DEPs, this intake will be divided into 3 meals and 2 to 4 snacks. Resources for women will include a low GI dietary food substitution list, a recipe booklet, and a tip sheet on how to lower dietary GI. Women will receive regular telephone-based coaching to advance goals. Phone-calls will be administered on a weekly basis during weeks 2-8 of the intervention, biweekly basis on weeks 10-12, and monthly basis on weeks 16-24.
Study NCT02687880 — intervention group
Intervention type: PROCEDURE
Intervention: Testicular biopsy
Description: Subjects will undergo a surgical procedure to harvest their testicular tissue.
Study NCT00509197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (sham inhaler)
Study NCT00509197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone
Description: Fluticasone 250mcg bid for one month
Study NCT04167397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collaborative learning
Description: Participants will be allocated to either single, dyad, triad or tetrad practice during initials skills training on an ultrasound simulator. Afterwards their competencies will be assessed with an individual transfer test on another simulator.
Study NCT03188549 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Softa-Man (Braun)
Description: Hand hygiene formula
Study NCT03188549 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Septol
Description: alcohol-based hand rub
Study NCT01969838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib
Description: Momelotinib tablet administered orally once daily
Study NCT01969838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ruxolitinib
Description: Ruxolitinib tablets administered orally twice daily
Study NCT01969838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match momelotinib
Description: Placebo to match momelotinib tablets administered orally once daily
Study NCT01969838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match ruxolitinib
Description: Placebo to match ruxolitinib tablets administered orally twice daily
Study NCT05395377 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Registered Dietitian/Nutritionist
Description: Participants received a FitBit Flex and Intensive Lifestyle Intervention coaching via telephone with Registered Dietitian/Nutritionist.
Study NCT05395377 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Prevention Program
Description: Modified DPP group classes lead by a Registered Dietitian and Exercise Physiologist.
Study NCT03466060 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RevitaLens : Opit-Free / RevitaLens : Clear Care
Description: Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
Study NCT02854722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox and calcium-vitamin D3
Description: deferasirox and calcium-vitamin D3 Deferasirox is an orodispersible tablet and should be taken daily 30 minutes before breakfast, with a dose of 10 mg/Kg/day ± 5 mg/Kg/day during 12 month.~Calcium 500 mg and vitamin D3 800 IU should also be taken daily as a basic therapy.